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Epithelial-mesenchymal transition (EMT) is a molecular
and cellular program in which epithelial cells lose their
well-differentiated phenotype and adopt mesenchymal
characteristics. This process occurs during the progression
of cancer to metastatic disease, and is also associated with
recurrence as conventional therapies fail to eliminate the
minority of resistant tumor cells that have undergone
EMT. Brachyury is a transcription factor that controls
EMT during development, and we have previously
reported that brachyury is aberrantly overexpressed in var-
ious human cancers where it promotes tumor cell EMT,
metastatic dissemination, and resistance to conventional
therapies. These studies led to the development of brachy-
ury-based antitumor vaccine approaches that are currently
in Phase I trials. However, we have recently shown that
very high expression of brachyury can protect against
caspase-dependent immune cell-mediated cytotoxicity [1].
In seeking to elucidate mechanisms of immunotherapy
resistance, we have discovered a novel positive association
between brachyury and the oncogenic cytoplasmic domain
of mucin-1 (MUC1-C). MUC1-C is overexpressed in the
majority of carcinomas, and it has been shown to confer
resistance to genotoxic agents. We found that overexpres-
sion or silencing of brachyury in isogenic pairs and single-
cell clones in colon, lung, pancreatic, and prostate cancer
cell lines leads to increased or decreased MUC1-C mRNA
and protein expression, respectively. We are currently
investigating the association between brachyury and
MUC1-C by immunohistochemical analysis of primary
and metastatic tumor tissues. Because MUC1-C promotes
resistance to cell death, we are also conducting experi-
ments to ascertain whether inhibition of MUC1-C by 1)
siRNA-mediated knockdown of MUC1-C, and 2) treat-
ment with a MUC1-C inhibitor (currently in Phase I trials)
reduces features of EMT, stemness, and resistance to
immunotherapy in tumor cells that express very high
levels of brachyury. Our ultimate goal is to demonstrate
that MUC1-C inhibition can be combined with brachyury-
based antitumor vaccine approaches to elicit potent
immune responses against mesenchymalized cancer cells
yielding durable tumor regression in vivo.
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